JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of PharmaCyte Biotech, Inc., a Nevada corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Dated: August 15, 2022
|IROQUOIS MASTER FUND LTD.|
|By:||Iroquois Capital Management, LLC,|
|its investment manager|
|IROQUOIS CAPITAL MANAGEMENT, LLC|
|IROQUOIS CAPITAL INVESTMENT GROUP LLC|